imatinib mesylate has been researched along with Connective Tissue Disease, Mixed in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Distler, JH; Distler, O; Manger, B; Schett, G; Spriewald, BM | 1 |
| Beyer, C; Distler, JH; Distler, O | 1 |
2 other study(ies) available for imatinib mesylate and Connective Tissue Disease, Mixed
| Article | Year |
|---|---|
Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Middle Aged; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrimidines; Treatment Outcome | 2008 |
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles | 2010 |